This is a working overview of research peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-27. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
== History of discovery == This analgesic activity of M6G (in animals) was first noted by Yoshimura. Subsequent work at St Bartholomew's Hospital, London in the 1980s, using a sensitive and specific high-performance liquid chromatography assay, accurately defined for the first time the metabolism of morphine, and the abundance of this metabolite (along with morphine-3-glucuronide, considered an inactive metabolite). It was postulated that kidney impairment would result in accumulation of the kidney-excreted active agent M6G, leading to potentially fatal toxicity such as respiratory depression. The frequent use of morphine in critically ill patients, and the common occurrence of kidney failure in this group implied that M6G accumulation could be a common, but previously unanticipated problem. The first studies demonstrated massive levels of M6G in 3 patients with kidney failure, which resolved as kidney function returned. Accumulation of M3G and M6G also decreased with return of kidney function after kidney transplantation. A key step in defining the importance of M6G in humans came in 1992 when the substance was artificially synthesised and administered to patients with pain, the majority of whom described pain relief.
Neoplasm: benign or malignant Granuloma: tuberculosis Infection: round pneumonia Vascular: infarct, varix, granulomatosis with polyangiitis, rheumatoid arthritis There are a number of features that are helpful in suggesting the diagnosis:
==== Early synthesis by the Buddha ==== According to Erich Frauwallner, the twelvefold chain resulted from the Buddha's combination of two lists. Originally, the Buddha explained the appearance of dukkha from tanha, "thirst", craving. Later on, the Buddha incorporated avijja, "ignorance", as a cause of suffering into his system. This is described in the first part of dependent origination. Frauwallner saw this "purely mechanical mixing" as "enigmatical", "contradictory" and a "deficiency in systematization". Paul Williams discusses Frauwallner's idea that the 12 links may be a composite. However, he ultimately concludes that "it may be impossible at our present stage of scholarship to work out very satisfactorily what the original logic of the full twelvefold formula was intended to be, if there ever was one intention at all."
== Ecology == Pisolithus arhizus is known to be quite durable; it is found in some unlikely places, tolerating intense soil conditions such as low ph and water concentration, or high temperatures and levels of metal contamination. Specifically, it is often found in soils with gravel and sand as well as in spots like ditches or lawns. Its ecological versatility was likely helpufl in achieving its Old World distribution in multiple continents (Europe, Africa, Asia). The Pisolithus genus as a whole is a known ectomycorrhizal group, meaning that it forms a symbiotic relationship with trees and their roots, in which both organisms mutually benefit. While Pisolithus in general is known to associate with over 50 host plants, P.arhizus is found most commonly with species of "pines, oaks, cedars, birch, Douglas-fir, hemlock, willow, poplar, beech." Ectomycorrhizal (ECM) fungi are known for aiding in plant growth and offering protection from different abiotic and biotic factors. They often work to accomplish mineral weathering in order to breakdown harsh rocks and soils, and reallocate these and other nutrients to their host plants. In return, plants supply fungi with carbon, and some estimates suggest some ECM relationships could even account for roughly a fifth of a tree's net carbon budget. P.arhizus specifically is shown to have positive performances on photosynthesis, biomass, and nutrient uptake. Numerous scientific studies on the complex symbiotic relationships of P. arhizus have proved its postitive ECM effects on a variety of host plants.
Sources: en.wikipedia.org
It can also be used in nuclear synthesis of higher mass elements; oganesson (element 118) was synthesized by bombarding californium-249 atoms with calcium-48 ions. Users of californium must take into account radiological concerns and the element's ability to disrupt the formation of red blood cells by bioaccumulating in skeletal tissue.
== Toxicity == Highly charged and heavy, alpha particles lose their several MeV of energy within a small volume of material, along with a very short mean free path. This increases the chance of double-strand breaks to the DNA in cases of internal contamination, when ingested, inhaled, injected or introduced through the skin. Otherwise, touching an alpha source is typically not harmful, as alpha particles are effectively shielded by a few centimeters of air, a piece of paper, or the thin layer of dead skin cells that make up the epidermis; however, the decay chain of many alpha emitting isotopes, for example Radium 226, contain daughter nuclei that undergo beta- and/or gamma-decay. Relative biological effectiveness (RBE) quantifies the ability of radiation to cause certain biological effects, notably either cancer or cell-death, for equivalent radiation exposure. Alpha radiation has a high linear energy transfer (LET) coefficient, which is about one ionization of a molecule/atom for every angstrom of travel by the alpha particle. The RBE has been set at the value of 20 for alpha radiation by various government regulations. The RBE is set at 10 for neutron irradiation, and at 1 for beta radiation and ionizing photons. However, the recoil of the parent nucleus (alpha recoil) gives it a significant amount of energy, which also causes ionization damage (see ionizing radiation). This energy is roughly the weight of the alpha (4 Da) divided by the weight of the parent (typically about 200 Da) times the total energy of the alpha.
In North Africa, Rhodesians in the 11th Hussars, 2nd Leicesters, 1st Cheshires and other regiments contributed to Operation Compass between December 1940 and February 1941 as part of the Western Desert Force under Major-General Richard O'Connor, fighting at Sidi Barrani, Bardia, Beda Fomm and elsewhere. This offensive was extremely successful, with the Allies suffering very few casualties—around 700 killed and 2,300 wounded and missing—while capturing the strategic port Tobruk, over 100,000 Italian soldiers and most of Cyrenaica. The Germans reacted by despatching the Afrika Korps under Erwin Rommel to shore up the Italian forces. Rommel led a strong counter-offensive in March–April 1941 that forced a general Allied withdrawal towards Egypt. German and Italian forces surrounded Tobruk but failed to take the largely Australian-garrisoned city, leading to the lengthy Siege of Tobruk. The Rhodesian contingents in the 11th Hussars, Leicesters, Buffs, Argylls, Royal Northumberland Fusiliers, Durham Light Infantry and Sherwood Foresters were transferred en masse to Kenya in February 1941 to join the new Southern Rhodesian Reconnaissance Regiment, which served in East Africa over the following year. The Rhodesians in the 1st Cheshires moved with that regiment to Malta the same month. The Rhodesian Signallers were withdrawn to Cairo to form a section handling high-speed communications between Middle East Command and General Headquarters in England.
Sources: en.wikipedia.org
=== Other uses and similar symbols === The main attribute of Vishnu is a wheel like weapon called the Sudarśanacakra. Similar wheel symbols were used as a solar symbol by the Ancient Egyptians. Some Buddha statues also depict the related Dharmachakra Mudrā, a hand sign depicting the turning of the Dharma wheel. A very similar wheel symbol also appears in the flag of the Romani people, hinting to their nomadic history. In non-Buddhist cultural contexts, an eight-spoked wheel resembles a traditional ship's wheel. As a nautical emblem, this image is a common sailor tattoo, which may be misidentified as a dharmachakra or vice versa. The sonnenrad is a similar symbol used by occultists and neo-nazis. Falun Gong uses the concept of a similar wheel as a central concept. In the Unicode computer standard, the dharmachakra is called the "Wheel of Dharma" and found in the eight-spoked form. It is represented as U+2638 (☸). As emoji: ☸️.
LTB4 is synthesized in vivo from LTA4 by the enzyme LTA4 hydrolase. Its primary function is to recruit neutrophils to areas of tissue damage, though it also helps promote the production of inflammatory cytokines by various immune cells. Drugs that block the actions of LTB4 have shown some efficacy in slowing the progression of neutrophil-mediated diseases.
== Illness and death == In June 2026, Chase was admitted to the Los Angeles General Medical Center for treatment of severe malnutrition following a period of extreme weight loss. During her hospitalization, her condition became increasingly critical after she was diagnosed with bacterial meningitis, several bloodstream infections, and AIDS. Doctors stated that she did not have much time left to live. To help manage rising medical expenses and support Chase in regaining stability, her alleged boyfriend, Roy Hernandez, created a GoFundMe crowdfunding campaign. In the campaign description, Hernandez said that Chase had faced significant personal difficulties in her post-acting life, including systemic bullying, a painful estrangement from her family, and ongoing housing instability in downtown Los Angeles. Chase died hours after the fundraising page was launched on June 16, from organ failure caused by her infections, substance abuse and AIDS. She was 35. A secondary cause of death was chronic polysubstance use. Hernandez publicly announced her death through TMZ the following day, June 17, stating that her bloodstream infections had led to septic complications that caused her body to shut down. Following her death, a dispute emerged regarding her final arrangements and the crowdfunding campaign, which Hernandez claimed was intended to help fund her cremation. Chase's former manager, John Ryan, and her father, John Schwallier, publicly denounced the fundraiser, advising fans not to donate.
amplification of the CCND1 gene / overexpression of cyclin D1; chromosomal translocation of the CCND1 gene; mutations in the degradation motif recognized by the CRL4-AMBRA1 E3 ubiquitin ligase; disruption of nuclear export and proteolysis of cyclin D1; induction of transcription by oncogenic Ras, Src, ErbB2 and STATs; Cyclin D1 overexpression is correlated with shorter cancer patient survival and increased metastasis. Amplification of the CCND1 gene is present in:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.